Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway
Open Access
- 6 January 2021
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 237 (2) , 166-178
Abstract
Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choice of a suitable topical treatment, the formulation matters and not just the active substances. This expert opinion paper was developed via a non-structured consensus process by Swiss dermatologists in hospitals and private practices to illustrate the current treatment options to general practitioners and dermatologists in Switzerland. Defining treatment goals together with the patient is crucial and increases treatment adherence. Patients’ personal preferences and pre-existing experiences should be considered and their satisfaction with treatment and outcome regularly assessed. During the induction phase of “classical” mild-to-moderate psoriasis, the fixed combination of topical calcipotriol (Cal) 50 μg/g and betamethasone dipropionate (BD) 0.5 mg/g once daily is frequently used for 4–8 weeks. During the maintenance phase, a twice weekly (proactive) management has proved to reduce the risk of relapse. Of the fixed combinations, Cal/BD aerosol foam is the most effective formulation. However, the individual choice of formulation should be based on a patient’s preference and the location of the psoriatic plaques. Tailored recommendations are given for the topical management of specific areas (scalp, facial, intertriginous/genital, or palmoplantar lesions), certain symptoms (hyperkeratotic or hyperinflammatory forms) as well as during pregnancy or a period of breastfeeding. As concomitant basic therapy, several emollients are recommended. If topical treatment alone does not appear to be sufficient, the regimen should be escalated according to the Swiss S1-guideline for the systemic treatment of psoriasis.Keywords
This publication has 48 references indexed in Scilit:
- S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trialBritish Journal of Dermatology, 2009
- Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label StudyDermatology, 2008
- Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric PatientsPediatric Dermatology, 2007
- Topical tacrolimus in the treatment of inverse psoriasis in childrenJournal of the American Academy of Dermatology, 2005
- Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasisJournal of Dermatological Treatment, 2005
- Psoriasis of the glans penis in a child successfully treated with ElidelR (pimecrolimus) creamJournal of the European Academy of Dermatology and Venereology, 2004
- A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasisBritish Journal of Dermatology, 1996
- A long-term assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasisJournal of Dermatological Treatment, 1996